GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instadose Pharma Corp (OTCPK:INSD) » Definitions » Capex-to-Operating-Cash-Flow

Instadose Pharma (Instadose Pharma) Capex-to-Operating-Cash-Flow : 0.00 (As of Feb. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Instadose Pharma Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Instadose Pharma's Capital Expenditure for the three months ended in Feb. 2022 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Feb. 2022 was $0.13 Mil.

Hence, Instadose Pharma's Capex-to-Operating-Cash-Flow for the three months ended in Feb. 2022 was 0.00.


Instadose Pharma Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Instadose Pharma's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instadose Pharma Capex-to-Operating-Cash-Flow Chart

Instadose Pharma Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial - - - - -

Instadose Pharma Quarterly Data
May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Instadose Pharma's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Instadose Pharma's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Instadose Pharma's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Instadose Pharma's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Instadose Pharma's Capex-to-Operating-Cash-Flow falls into.



Instadose Pharma Capex-to-Operating-Cash-Flow Calculation

Instadose Pharma's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Nov. 2021 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / 0
=N/A

Instadose Pharma's Capex-to-Operating-Cash-Flow for the quarter that ended in Feb. 2022 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / 0.126
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Instadose Pharma  (OTCPK:INSD) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Instadose Pharma Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Instadose Pharma's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Instadose Pharma (Instadose Pharma) Business Description

Traded in Other Exchanges
N/A
Address
5500 North Service Road, Suite 301, Burlington, ON, CAN, L7L 6W6
Instadose Pharma Corp, formerly Mikrocoze Inc is seeking to create a global distribution platform for medicinal cannabis and cannabinoid oil. The company endeavors to utilize the Global Distribution Platform to open the commercial gateway to a new wholesale marketplace along with providing pharmaceutical industry companies with large, sustainable, consistent, diverse, and low?cost supplies of high?quality medicinal cannabis and cannabinoid oil for use in bulk as an active pharmaceutical ingredient.

Instadose Pharma (Instadose Pharma) Headlines

From GuruFocus